CDER

Drug Registration and Listing System

Requirements for drug establishment registration and drug listing are set forth in Section 510 of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), Section 351 of the Public Health Service Act (the PHS Act), and in the Code of Federal Regulations (CFR) Title 21 Part 207.

Changes in the FD&C Act, resulting from the Food and Drug Administration Amendments Act (FDAAA) of 2007 (Public Law 110-85), require that drug establishment registration and drug listing information be submitted electronically unless a waiver is granted. As a result, since June 1, 2009, the FDA no longer accepts paper submissions for drug establishment registration and listing unless a waiver is granted. Moving from a paper-based format to an electronic system will improve the timeliness and accuracy of the submissions.

For your reference, see Guidance - Drug Establishment Registration and Drug Listing

IMPORTANT! To submit your file to the FDA, you must first obtain a Webtrader account with the FDA Electronic Submission Gateway (ESG). To do this, visit the Setting up a WebTrader Account Checklist.

Individual Case Safety Reporting System (ICSR)

The ICSR (also known as the Drug Adverse Event Reporting System) provides the capability to report adverse drug events and submit structured electronic data in compliance with the approved ICSR data standard. This tool provides users an effortless mechanism to generate the FDA-compatible ICSR files. Once ICSR information is entered into the template, the ICSR file is automatically generated and can be submitted through the Electronic Submissions Gateway (ESG).

IMPORTANT! To submit your file to the FDA, you must first obtain a Webtrader account with the FDA Electronic Submission Gateway (ESG). To do this, visit the Setting up a WebTrader Account Checklist.

Generic Drug Facility Electronic Self-Identification

The Generic Drug User Fee Amendments of 2012 (GDUFA), requires the identification of facilities, sites and organizations involved in the manufacture of human generic drugs and associated active pharmaceutical ingredients.  By October 1, 2012, FDA will publish notice of the self-identification requirement in the Federal Register.  Upon publication, business entities will have 60 days to complete the self-identification process.  Please note that the requirement for self-identification is distinct from the requirement to register and list.
Answers to specific questions about the GDUFA self-identification can be found in Guidance for industry Self-Identification of Generic Drug Facilities, Sites and Organizations including which organizations need to self-identify, what information they are required to submit, and the means and format for submission of required information.  Additional information about GDUFA is available at www.fda.gov/gdufa. 

Self-identification files may be generated using eSubmitter, or any of the following other SPL tools: 

1.  Xforms available at:  http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm189651.htm.  Step-by-step instructions for electronically creating, validating, and submitting self-identification information using Xforms are available at:  http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm; or

2. Software tools developed internally by generic manufacturers utilizing the SPL technical specifications.  Additional information is available at:  http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm.

3. Other commercially available applications (e.g., vendor tools). 

IMPORTANT! To submit your file to the FDA, you must first obtain a WebTrader account with the FDA Electronic Submission Gateway (ESG).  See Setting up a WebTrader Account Checklist.